Please login to the form below

Not currently logged in
Email:
Password:

GSK paid $1bn to settle Paxil lawsuits

GlaxoSmithKline (GSK) has paid almost $1bn to resolve lawsuits over its antidrepressant Paxil since it was introduced in 1993

GlaxoSmithKline (GSK) has paid almost $1bn to resolve lawsuits over its antidrepressant Paxil since it was introduced in 1993. Analysts have said the amount is higher than what was expected.

The total paid by the UK's largest pharmaceutical company includes around $390m for cases regarding suicides or attempted suicides reportedly linked to the drug; a further $200m to settle lawsuits of addiction and birth defects; and $400m over antitrust and fraud claims.

However, the $1bn does not include the additional 600+ outstanding claims that Paxil caused birth defects. Only 10 such cases have been settled, at an average cost of $4m to GSK. In one case, settled in October 09, GSK was ordered to pay $2.5m in compensatory damages. Based on these figures, the company may face an additional liability of around $1.5bn.

GSK has declined to confirm the $1bn figure. Spokesperson Sarah Alspach said: "Paxil has been on the market in the US since 1993. Like many other pharmaceutical products, it has been the subject of different kinds of litigation over the years. It would be inappropriate and potentially misleading to aggregate payments in these various types of litigation."

15th December 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
BASTARD . LONDON

BASTARD . LONDON collaborates with you to amplify brand ideas into a visual brand language that resonates and engages with...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics